Zelnecirnon, also known as RPT193, is a CCR4 antagonist that blocks the recruitment of Th2 cells in order to treat inflammatory diseases (taken orally). The Phase 1b trial, which was conducted in patients with atopic dermatitis, found that markable improvement occurred after 4 weeks with little side effects. A Phase 2 clinical trial is currently being conducted to evaluate the efficacy and safety of Zelnecirnon, with an expected end date of September 2023.
MedKoo Cat#: 130068
Name: Zelnecirnon
CAS#: 2366152-15-8
Chemical Formula: C27H34Cl3N5O2
Exact Mass: 565.1778
Molecular Weight: 566.95
Elemental Analysis: C, 57.20; H, 6.04; Cl, 18.76; N, 12.35; O, 5.64
The following data is based on the product molecular weight 566.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
